Key result
Higher red cell distribution width-to-albumin ratio linked to ~42% greater 12-month event risk per SD.
Its licence doesn't allow us to show a copy here.
Why the study?
The incremental prognostic value and performance of red cell distribution width-to-albumin ratio in contemporary SGLT2i-treated heart failure cohorts remain uncertain.
Does baseline red cell distribution width-to-albumin ratio (RAR) predict 12-month clinical outcomes in patients with heart failure treated with SGLT2 inhibitors?
Cohort (n=641)
Does baseline red cell distribution width-to-albumin ratio (RAR) predict 12-month clinical outcomes in patients with heart failure treated with SGLT2 inhibitors?
Hazard Ratio: 1.42 (95% CI 1.24–1.61)
Baseline red cell distribution width-to-albumin ratio provides modest but significant prognostic information for predicting 12-month adverse events in heart failure patients initiating SGLT2 inhibitors.
BACKGROUND: Red cell distribution width-to-albumin ratio (RAR) is associated with heart failure (HF) prognosis, but its incremental value and performance in contemporary sodium-glucose cotransporter 2 inhibitor (SGLT2i)-treated cohorts remain uncertain. METHODS: We re-audited a prospective registry and analyzed 641 unique patients with HF and baseline RAR measured before or on the day of SGLT2i initiation. The 12-month primary endpoint was all-cause death, unplanned hospitalization, or emergency department visit; event-free patients were right-censored at last contact or 365 days. RESULTS: There were 199 first events in the full time-to-event cohort. RAR remained associated with the endpoint after adjustment including N-terminal pro B-type natriuretic peptide [hazard ratio (HR) 1.42 per standard deviation, 95% confidence interval (CI) 1.24-1.61]. The HR for death or HF hospitalization was 1.57 (95% CI 1.33-1.86). Adding RAR increased Harrell's C-index modestly from 0.694 to 0.710 (likelihood-ratio p < 0.001). No statistically significant interaction was observed by SGLT2i type or initiation setting. CONCLUSIONS: Baseline RAR provides modest, confirmatory prognostic information in SGLT2i-treated HF but is not established as a treatment-response biomarker or stand-alone decision rule.
No takes yet. Share an insight, caveat, or question.
Jurin et al. (2026) conducted a cohort in Heart failure (n=641). Baseline red cell distribution width-to-albumin ratio (RAR) was evaluated on All-cause death, unplanned hospitalization, or emergency department visit (HR 1.42, 95% CI 1.24-1.61). Baseline red cell distribution width-to-albumin ratio was associated with an increased risk of 12-month death, hospitalization, or emergency visit (HR 1.42 per standard deviation; 95% CI 1.24-1.61).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: